<DOC>
	<DOCNO>NCT02708095</DOCNO>
	<brief_summary>The main purpose study evaluate efficacy safety study drug know baricitinib participant systemic lupus erythematosus .</brief_summary>
	<brief_title>A Study Baricitinib ( LY3009104 ) Participants With Systemic Lupus Erythematosus ( SLE )</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Have receive diagnosis SLE least 24 week prior screen , meet American College Rheumatology ( ACR ) 1982 revise criterion OR 2012 Systemic Lupus Erythematosus International Collaborating Clinics ( SLICC ) criterion . Have positive antinuclear antibody ( ANA ) ( titer ≥1:80 ) and/or positive antidoublestranded deoxyribonucleic acid ( dsDNA ) assess central laboratory screening . Have SLEDAI2K score ≥4 base clinical symptom ( include lab value ) randomization . Have active arthritis and/or active rash define SLEDAI2K randomization . Have active severe lupus nephritis . Have active severe central nervous system ( CNS ) lupus . Have history presence cardiovascular , respiratory , hepatic , gastrointestinal , endocrine , hematological , neurological , neuropsychiatric disorder serious and/or unstable illness , opinion investigator , could constitute unacceptable risk take investigational product interfere interpretation data . Have current recent clinically serious viral , bacterial , fungal , parasitic infection . Are currently receive oral corticosteroid dose &gt; 20milligrams per day prednisone ( equivalent ) adjust dose corticosteroid within 2 week plan randomization . Have start treatment adjust dose nonsteroidal antiinflammatory drug ( NSAIDs ) ( NSAID use intend treatment sign symptom SLE ) within 4 week plan randomization . Have start treatment adjust dose antimalarial within 12 week plan randomization . Have start treatment adjust dose immunosuppressant within 12 week plan randomization . Have receive cyclophosphamide ( cytotoxic agent ) within 12 week prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>